FDA Clears Ascletis’s ASC30 for 13-Week Phase II Diabetes Trial with 100 Patients
Ascletis secured FDA IND clearance for its oral GLP-1 agonist ASC30 in a 13-week, randomized, double-blind, placebo-controlled Phase II trial enrolling ~100 type 2 diabetes patients. Participants will be randomized 2:3:3:2 to 40 mg, 60 mg, 80 mg or placebo to evaluate HbA1c, fasting glucose, body weight and safety, with Q1 2026 enrollment planned.
1. Novo Nordisk Broadly Launches First Oral GLP-1 Weight Loss Pill in the U.S.
On January 5, 2026, Novo Nordisk commenced nationwide distribution of its Wegovy® oral GLP-1 formulation, marking the first once-daily pill for chronic weight management. The product is now stocked at over 70,000 retail pharmacies, including national chains and select telehealth providers, with a self-pay offer starting at $149 per month for the 1.5 mg starter dose. Broad availability through pharmacy networks, telehealth platforms and NovoCare® Pharmacy is expected to accelerate patient uptake by offering a convenient alternative to weekly injections and expanding access to the roughly 100 million Americans living with obesity or overweight with related comorbidities.
2. Weight Watchers Integrates Oral GLP-1 into Med+ Program, Driving Superior Real-World Outcomes
WW International announced that its Weight Watchers Clinic, a NovoCare® Recognized Care Provider, has integrated the Wegovy® pill into its Med+ program and GLP-1 Success Program. By combining once-daily oral GLP-1 access with board-certified clinical care, evidence-based behavioral science, personalized coaching and digital tools, engaged members achieve significantly greater weight loss. Internal analyses show that at one month, Med+ participants who regularly engaged in the GLP-1 Success Program lost 61.3% more body weight on average versus non-engaged peers, and at twelve months, they lost 29.1% more. This integrated model underscores the value of pairing medication with structured support to improve adherence and long-term outcomes.
3. OASIS 4 Phase 3 Trial Validates Efficacy and Tolerability of Wegovy® Oral Tablet
Data from the 64-week OASIS 4 trial demonstrated that participants on Wegovy® 25 mg tablets achieved an average weight reduction of 16.6% versus 2.7% with placebo under a trial product estimand, and 13.6% versus 2.4% under a treatment policy estimand. Safety and adverse event profiles mirrored those seen with the injectable formulation, with gastrointestinal symptoms such as nausea and diarrhea being the most common. The strong efficacy and familiar tolerability profile position the oral GLP-1 as a differentiated market entrant, capable of capturing a meaningful share of the projected US weight-loss drug market estimated to reach tens of billions by the end of the decade.